JP2010505443A - 分娩時の頭皮血液における低酸素症を確認する方法 - Google Patents
分娩時の頭皮血液における低酸素症を確認する方法 Download PDFInfo
- Publication number
- JP2010505443A JP2010505443A JP2009532327A JP2009532327A JP2010505443A JP 2010505443 A JP2010505443 A JP 2010505443A JP 2009532327 A JP2009532327 A JP 2009532327A JP 2009532327 A JP2009532327 A JP 2009532327A JP 2010505443 A JP2010505443 A JP 2010505443A
- Authority
- JP
- Japan
- Prior art keywords
- plasma
- ldh
- blood
- compartment
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004369 blood Anatomy 0.000 title claims abstract description 75
- 239000008280 blood Substances 0.000 title claims abstract description 75
- 238000000034 method Methods 0.000 title claims abstract description 63
- 206010021143 Hypoxia Diseases 0.000 title claims abstract description 52
- 230000007954 hypoxia Effects 0.000 title claims abstract description 45
- 210000004761 scalp Anatomy 0.000 title claims abstract description 38
- 102000003855 L-lactate dehydrogenase Human genes 0.000 claims abstract description 87
- 108700023483 L-lactate dehydrogenases Proteins 0.000 claims abstract description 87
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 52
- 239000004310 lactic acid Substances 0.000 claims abstract description 26
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 26
- 238000012384 transportation and delivery Methods 0.000 claims abstract description 24
- 230000001605 fetal effect Effects 0.000 claims abstract description 17
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 17
- 210000003754 fetus Anatomy 0.000 claims abstract description 16
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 14
- 238000005259 measurement Methods 0.000 claims abstract description 13
- 229910052700 potassium Inorganic materials 0.000 claims abstract description 10
- 208000037212 Neonatal hypoxic and ischemic brain injury Diseases 0.000 claims description 26
- 208000033300 perinatal asphyxia Diseases 0.000 claims description 26
- 210000004027 cell Anatomy 0.000 claims description 25
- 239000012528 membrane Substances 0.000 claims description 22
- 206010070511 Hypoxic-ischaemic encephalopathy Diseases 0.000 claims description 20
- 208000009973 brain hypoxia - ischemia Diseases 0.000 claims description 20
- 238000012360 testing method Methods 0.000 claims description 16
- 238000001514 detection method Methods 0.000 claims description 15
- 238000000926 separation method Methods 0.000 claims description 15
- 210000000601 blood cell Anatomy 0.000 claims description 13
- 238000007689 inspection Methods 0.000 claims description 11
- 239000003153 chemical reaction reagent Substances 0.000 claims description 8
- 230000001146 hypoxic effect Effects 0.000 claims description 8
- 230000001154 acute effect Effects 0.000 claims description 6
- 239000007790 solid phase Substances 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 3
- 238000004891 communication Methods 0.000 claims description 3
- 239000011159 matrix material Substances 0.000 claims description 3
- 238000010241 blood sampling Methods 0.000 claims 1
- 239000006228 supernatant Substances 0.000 claims 1
- 238000011144 upstream manufacturing Methods 0.000 claims 1
- 230000000007 visual effect Effects 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 description 38
- 239000011777 magnesium Substances 0.000 description 30
- 206010018910 Haemolysis Diseases 0.000 description 18
- 230000008588 hemolysis Effects 0.000 description 18
- 238000004458 analytical method Methods 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- 239000011575 calcium Substances 0.000 description 10
- 239000003550 marker Substances 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 9
- 208000010444 Acidosis Diseases 0.000 description 8
- 210000000056 organ Anatomy 0.000 description 8
- 230000035945 sensitivity Effects 0.000 description 8
- 206010003497 Asphyxia Diseases 0.000 description 7
- 230000007950 acidosis Effects 0.000 description 7
- 208000026545 acidosis disease Diseases 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 6
- 206010028923 Neonatal asphyxia Diseases 0.000 description 5
- 239000003792 electrolyte Substances 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 210000004700 fetal blood Anatomy 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 210000001215 vagina Anatomy 0.000 description 5
- 230000009471 action Effects 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 210000002458 fetal heart Anatomy 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 208000029028 brain injury Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- -1 polyethylene Polymers 0.000 description 3
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- 102000004420 Creatine Kinase Human genes 0.000 description 2
- 108010042126 Creatine kinase Proteins 0.000 description 2
- 208000034423 Delivery Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 210000004381 amniotic fluid Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000006931 brain damage Effects 0.000 description 2
- 231100000874 brain damage Toxicity 0.000 description 2
- 206010008129 cerebral palsy Diseases 0.000 description 2
- 230000035606 childbirth Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000008816 organ damage Effects 0.000 description 2
- 230000032696 parturition Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 208000006893 Fetal Hypoxia Diseases 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-VSOAQEOCSA-N L-altropyranose Chemical compound OC[C@@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-VSOAQEOCSA-N 0.000 description 1
- 108010088350 Lactate Dehydrogenase 5 Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010027417 Metabolic acidosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000035010 Term birth Diseases 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- HPYIIXJJVYSMCV-MGDXKYBTSA-N astressin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]1C(N[C@@H](C)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@@H](CCCCNC(=O)CC1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)=O)C(C)C)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CNC=N1 HPYIIXJJVYSMCV-MGDXKYBTSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000004159 blood analysis Methods 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000002064 heart cell Anatomy 0.000 description 1
- 108010036302 hemoglobin AS Proteins 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 108010087599 lactate dehydrogenase 1 Proteins 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 238000000838 magnetophoresis Methods 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000037891 myocardial injury Diseases 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 238000001139 pH measurement Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 238000012123 point-of-care testing Methods 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical group FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
- C12Q1/32—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B10/00—Other methods or instruments for diagnosis, e.g. instruments for taking a cell sample, for biopsy, for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
- A61B10/0045—Devices for taking samples of body liquids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B10/00—Other methods or instruments for diagnosis, e.g. instruments for taking a cell sample, for biopsy, for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
- A61B10/0045—Devices for taking samples of body liquids
- A61B10/0048—Devices for taking samples of body liquids for taking amniotic fluid samples
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14542—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring blood gases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/157—Devices characterised by integrated means for measuring characteristics of blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
- A61B5/412—Detecting or monitoring sepsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/43—Detecting, measuring or recording for evaluating the reproductive systems
- A61B5/4306—Detecting, measuring or recording for evaluating the reproductive systems for evaluating the female reproductive systems, e.g. gynaecological evaluations
- A61B5/4343—Pregnancy and labour monitoring, e.g. for labour onset detection
- A61B5/4362—Assessing foetal parameters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F7/00—Heating or cooling appliances for medical or therapeutic treatment of the human body
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
- C12Q1/52—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving transaminase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G01N33/492—Determining multiple analytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B2503/00—Evaluating a particular growth phase or type of persons or animals
- A61B2503/02—Foetus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/14—Devices for taking samples of blood ; Measuring characteristics of blood in vivo, e.g. gas concentration within the blood, pH-value of blood
- A61B5/1405—Devices for taking blood samples
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14546—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/15—Devices for taking samples of blood
- A61B5/150007—Details
- A61B5/150015—Source of blood
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/902—Oxidoreductases (1.)
- G01N2333/904—Oxidoreductases (1.) acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/91188—Transferases (2.) transferring nitrogenous groups (2.6)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7038—Hypoxia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Surgery (AREA)
- Medical Informatics (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Vascular Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Optics & Photonics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Ecology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
Abstract
【選択図】なし
Description
2使い捨てカード
3検査用分析装置
4ガラス製キャピラリー
5(代替)検査デバイス
6頭皮
7血液試料
7‘血漿
7‘’血液細胞
8固相化学手段
10カニューレ
11膜
12グリッド
13コンパートメントの底部
14コンパートメントの側壁
15導管
16バルブ
20検出セル
21チャンバー
22バーコード
23インターフェース
24試料スプリッタ
25血漿分離デバイス
26プリント試薬
30デバイス
31プロセッサ
32ディスプレイ
33データ出力
34バーコード読み取り装置
35ハウジング
51チャネル
52前チャンバー
53ポンプデバイス
54チェックバルブ
55使い捨てコンパートメント
56カラーデバイス
57穴
58フィルタ
59分析チャンバー
501バッファー用チャンバー
Claims (28)
- 血液試料(7)から得られた血漿(7’)中の全乳酸脱水素酵素(LDH)の測定を含んでいて、分娩時の血液試料(7)の採取および低酸素症を確認する少なくとも1つの指標を探すための血液試料(7)の処理を含む胎児頭皮血液における急性低酸素症を確認する、方法。
- 前記試料(7)が、5 μL〜60 μLである、請求項1の方法。
- 前記試料(7)が、5 μL〜25 μLである、請求項1の方法。
- 前記試料(7)が、約5 μL〜15 μLである、請求項1の方法。
- 半透過性膜(11;25)および/またはフィルタ(58)を用いて、血液細胞(7’’)から血漿(7’)を分離することを含む、請求項1〜請求項4のいずれか1つの方法。
- 前記膜(11;25;58)の面積が、5 mm2〜1000 mm2、好ましくは100 mm2未満である、請求項5の方法。
- 前記膜(11;25:58)の片面に前記試料(7)を負荷するステップと、前記膜のもう1つの面に陰圧をかけるステップと、前記もう1つの面が正面であるコンパートメント(14;20C、D;52)中の血漿(7’)を採取するステップとを含む、請求項5または6の方法。
- 前記血漿(7’’)を前記コンパートメント(14;20C、D;52)からLDHを測定する装置および/またはデバイス(59)に移すステップを含む、請求項7の方法。
- 前記コンパートメント(20C〜D)に蓄積した前記血漿(7’)中のLDHを測定するステップを含む、請求項7の方法。
- 前記膜が、キャピラリー力によって引き寄せられた血漿(7’)が入る多孔質マトリックスに配置または統合される、請求項5の方法。
- 前記膜が、前記マトリックスにおいて規定の時間でLDHを測定した後に除去される、請求項10の方法。
- 前記試料中の血液細胞から血漿を分離するステップと、LDHを測定するため前記血漿の上清を装置に移すステップとを含む、請求項1〜請求項4の方法。
- このように測定されたLDHと分娩時に非低酸素症状態の胎児から採取された胎児頭皮血液から得られた血漿にて測定されたLDHとを前記比較することをさらに含む、請求項1〜請求項12の方法。
- 統計的に有意なLDH高値が低酸素症を示す、請求項13の方法。
- 3種類以上の因子による統計的に有意なLDH高値が低酸素性虚血性脳症を示す、請求項13の方法。
- 前記頭皮血液(7)および/または前記血漿(7’)中のK、Mg、Ca、AST、ALT、および乳酸からなる前記群の1種類または数種類を測定することをさらに含む、請求項1〜請求項15のいずれかの方法。
- 統計的に有意なK、Mg、Ca、AST、ALT、および乳酸高値と統計的に有意なLDH高値は、低酸素症を示す。
- 血漿(7’)を分離する手段(25、58)と、LDHを検出するために配置されたコンパートメント(20C、D;59)を含む使い捨てデバイス(2、5)に前記試料(7)が採取される、請求項1〜請求項17のいずれかによる方法。
- 前記装置が、ハウジング(17;50;25)と、前記ハウジング内のコンパートメント(14;52;25)と、半透過性膜(11;58;25B)により被覆された前記ハウジングにおける第1開口部と、陰圧手段または導管(15;51)を用いたキャピラリー力手段を用いて前記コンパートメントと連絡する前記ハウジングにおける第2開口部と、陰圧により前記連絡をコントロールするバルブ手段(16;53)とを含む、請求項1〜請求項18のいずれかの前記方法にて、血液細胞から血漿を分離する装置の、使用。
- 前記バルブ手段が前記導管(15;51)に配置されていて、好ましくは前記コンパートメントがその底部と連絡するよう配列され、前記コンパートメントの前記底部に蓄積した血漿の排出能を調節する第2のバルブ手段を備えた第2導管をさらに含んでいる、請求項19の使用。
- 前記コンパートメントが、前記ハウジング内に蓄積した前記血漿中のLDHを測定する手段を格納する、またはこれと連絡する、請求項19または請求項20の使用。
- 前記検査システムが、前記血漿(7’)中の全乳酸脱水素酵素(LDHを間接的または直接的に測定するよう配置される血液試料採取部分(21、33;57)と、血漿分離デバイス(25;58)と、コンパートメント(20C;59)とを備える、請求項1〜請求項18のいずれかによる前記方法を実行するための、検査システム。
- 前記受け部分(21、23)がコンパートメントおよびキャピラリー試料採取器(4)用インターフェースを形成する、前記使い捨てデバイス(2)が平らな形体(23)を有している、請求項22による検査システム。
- 前記カード上に多数の検出コンパートメント(20A〜20E)が配置されていて、好ましくは試薬を用いて前記コンパートメント(20A〜20C)のいずれか1つが上流コンパートメント(26A〜26E)と連結される、請求項23による検査システム。
- 前記インターフェース(23)と前記血漿分離デバイス(25)との間に試料スプリッタ(24)がある、請求項22〜請求項24のいずれかによる、検査システム。
- 前記コンパートメント(20A〜20E)が光検出セルの形状をしていて、前記本体(23)が少なくとも1つのデバイス(30A〜30E)に配置される装置(3)に適合するよう形成されている、請求項23および/または請求項24による検査システム。
- 前記本体(23)には固有のコード(22)が配置されていて、好ましくは前記装置(3)が読み取り装置(34)を備えている、請求項22による検査システム。
- 前記使い捨てデバイス(5)が、視覚的検出用の固相化学手段(8)が配置されたコンパートメントを含む、請求項22による検査システム。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE0602158A SE530596C2 (sv) | 2006-10-13 | 2006-10-13 | Metod att fastställa syrebrist i blod från skalpen under förlossning |
SE0602158-8 | 2006-10-13 | ||
PCT/SE2007/050738 WO2008054303A2 (en) | 2006-10-13 | 2007-10-12 | Method of determining hypoxia in scalp blood during labour |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010505443A true JP2010505443A (ja) | 2010-02-25 |
JP5655307B2 JP5655307B2 (ja) | 2015-01-21 |
Family
ID=39344721
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009532327A Active JP5655307B2 (ja) | 2006-10-13 | 2007-10-12 | 分娩時の頭皮血液における低酸素症を確認する方法 |
Country Status (6)
Country | Link |
---|---|
US (2) | US8945824B2 (ja) |
EP (1) | EP2089535A4 (ja) |
JP (1) | JP5655307B2 (ja) |
CN (1) | CN101535497A (ja) |
SE (1) | SE530596C2 (ja) |
WO (1) | WO2008054303A2 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013506833A (ja) * | 2009-09-30 | 2013-02-28 | カルマーク スウェーデン アクチエボラグ | 低酸素誘導性の細胞損傷を測定する検査システム |
JP2021508048A (ja) * | 2017-12-20 | 2021-02-25 | ラジオメーター・メディカル・アー・ペー・エス | インビトロ溶血検出及び全血サンプル中の少なくとも1つの血液パラメータの補正 |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE530596C2 (sv) | 2006-10-13 | 2008-07-15 | Mathias Karlsson | Metod att fastställa syrebrist i blod från skalpen under förlossning |
EP2396419A4 (en) * | 2008-04-11 | 2012-09-26 | Calmark Sweden Aktiebolag | METHOD FOR DETERMINING HYPOXIA |
WO2010143189A1 (en) * | 2009-06-09 | 2010-12-16 | Monitus Ltd. | Fetal lactic acid monitor |
SE535502C2 (sv) | 2010-09-14 | 2012-08-28 | Calmark Sweden Ab | System och metod för att analysera risk eller förekomst av organsvikt |
JP2014503500A (ja) | 2010-11-18 | 2014-02-13 | シンタ ファーマスーティカルズ コーポレーション | 低酸素状態に基づく酸素感受性薬剤による治療に適した被験体の事前選択 |
US20120128580A1 (en) | 2010-11-18 | 2012-05-24 | Synta Pharmaceuticals Corp. | Preselection of subjects for therapeutic treatment with elesclomol based on hypoxic status |
AU2011329681A1 (en) | 2010-11-18 | 2013-05-30 | Synta Pharmaceuticals Corp. | Preselection of subjects for therapeutic treatment based on hypoxic status |
SE536430C2 (sv) * | 2011-11-23 | 2013-10-29 | Calmark Sweden Ab | Testsystemarrangemang och metod för testning |
SE536431C2 (sv) * | 2011-11-23 | 2013-10-29 | Calmark Sweden Ab | Testsystemarrangemang och metod för testning |
US9808470B2 (en) * | 2012-04-19 | 2017-11-07 | Universite De Liege | Estrogenic components for use in the treatment of neurological disorders |
WO2013170182A1 (en) | 2012-05-11 | 2013-11-14 | Synta Pharmaceuticals Corp. | Treating cancer with an hsp90 inhibitory compound |
US20150366493A1 (en) * | 2012-09-17 | 2015-12-24 | Brains Online Holding B.V. | Rod shaped implantable biosensor |
US11103159B2 (en) * | 2016-03-04 | 2021-08-31 | United States Of America As Represented By The Secretary Of The Air Force | Exhaled breath hypoxia biomarkers |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS626167A (ja) * | 1985-06-03 | 1987-01-13 | イ−ストマン コダック カンパニ− | 全乳酸デヒドロゲナ−ゼ量の測定用分析要素及びその測定方法 |
JPH04501768A (ja) * | 1988-09-15 | 1992-03-26 | アイ―スタット コーポレーション | 実時間流体分析用使い捨て可能な検知装置 |
JPH09504608A (ja) * | 1993-10-04 | 1997-05-06 | アイ−スタット コーポレーション | 体液試料中の溶血を検出するための方法および装置 |
WO2006121510A2 (en) * | 2005-05-09 | 2006-11-16 | Theranos, Inc. | Point-of-care fluidic systems and uses thereof |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2061984C3 (de) * | 1970-12-16 | 1974-04-11 | Boehringer Mannheim Gmbh, 6800 Mannheim | Reagens zur Bestimmung der Lactat-Dehydrogenase im Farbtest |
US3783105A (en) * | 1971-01-27 | 1974-01-01 | Geomet | Apparatus for assaying enzyme activity |
SU545335A1 (ru) * | 1974-05-24 | 1977-02-05 | Днепропетровский Ордена Трудового Красного Знамени Медицинский Институт | Способ диагностики кислородной недостаточности |
US4006061A (en) * | 1975-12-29 | 1977-02-01 | Monsanto Company | Lactate dehydrogenase determination method |
SU670300A1 (ru) * | 1978-01-30 | 1979-06-30 | Всесоюзный Научно-Исследовательский Институт Акушерства И Гинекологии | Способ диагностики нарушени состо ни новорожденного во врем родов |
US4441510A (en) * | 1980-07-25 | 1984-04-10 | Worley Michael W | Method and apparatus for fetal pH scalp studies |
FR2511872A1 (fr) * | 1981-08-25 | 1983-03-04 | Messier Denis | Dispositif perfectionne pour separer le plasma des globules du sang |
US4839296A (en) * | 1985-10-18 | 1989-06-13 | Chem-Elec, Inc. | Blood plasma test method |
US4935346A (en) * | 1986-08-13 | 1990-06-19 | Lifescan, Inc. | Minimum procedure system for the determination of analytes |
SU1695891A1 (ru) * | 1989-06-28 | 1991-12-07 | Московский областной научно-исследовательский институт акушерства и гинекологии | Способ диагностики гипоксии плода в антенатальном периоде |
US5377673A (en) * | 1993-03-22 | 1995-01-03 | Van Dell; Peter | Intrauterine monitoring device |
RU2144673C1 (ru) | 1998-04-02 | 2000-01-20 | Ивановская государственная медицинская академия | Способ прогнозирования гепатоцеллюлярной недостаточности у детей раннего возраста, перенесших перинатальную гипоксию |
AU7748200A (en) * | 1999-09-30 | 2001-04-30 | Varian Associates, Inc. | Hypoxia-related human genes, proteins, and uses thereof |
US6423011B1 (en) * | 2000-03-02 | 2002-07-23 | Clinical Innovation Associates, Inc. | Apparatus and method for fetal scalp blood sampling |
RU2200466C2 (ru) | 2001-05-25 | 2003-03-20 | Нижегородский государственный научно-исследовательский институт травматологии и ортопедии | Способ региональной диагностики состояния тканевого комплекса при его аутотрансплантации в условиях воспалительно измененного реципиентного ложа |
NL1018249C2 (nl) * | 2001-06-08 | 2002-12-10 | Tno | Inrichting voor het bepalen van foetale reserves tijdens een bevalling. |
US20030232396A1 (en) * | 2002-02-22 | 2003-12-18 | Biolife Solutions, Inc. | Method and use of protein microarray technology and proteomic analysis to determine efficacy of human and xenographic cell, tissue and organ transplant |
US8741557B2 (en) | 2003-02-14 | 2014-06-03 | Beth Israel Deaconess Medical Center, Inc. | Predicting graft rejection |
CN1829477A (zh) | 2003-09-15 | 2006-09-06 | 产科保健公司 | 监测分娩过程的方法 |
JP3809457B2 (ja) * | 2004-05-17 | 2006-08-16 | 積水化学工業株式会社 | 血液分離フィルタ装置、および真空検体採取管 |
ITMI20050881A1 (it) | 2005-05-16 | 2006-11-17 | Anna Favre | Kit diagnostico per la malattia di hirschsprung megalon congenito |
WO2007000877A1 (ja) * | 2005-06-28 | 2007-01-04 | Matsushita Electric Industrial Co., Ltd. | 血清中の乳酸脱水素酵素活性の測定方法、および血清中の乳酸脱水素酵素活性の測定装置 |
JP2007159658A (ja) * | 2005-12-09 | 2007-06-28 | Fujifilm Corp | 採血針 |
SE530596C2 (sv) | 2006-10-13 | 2008-07-15 | Mathias Karlsson | Metod att fastställa syrebrist i blod från skalpen under förlossning |
-
2006
- 2006-10-13 SE SE0602158A patent/SE530596C2/sv unknown
-
2007
- 2007-10-12 EP EP07835323.2A patent/EP2089535A4/en not_active Withdrawn
- 2007-10-12 CN CNA2007800377114A patent/CN101535497A/zh active Pending
- 2007-10-12 WO PCT/SE2007/050738 patent/WO2008054303A2/en active Application Filing
- 2007-10-12 JP JP2009532327A patent/JP5655307B2/ja active Active
-
2008
- 2008-04-11 US US12/101,470 patent/US8945824B2/en active Active
-
2015
- 2015-01-08 US US14/592,098 patent/US20150127078A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS626167A (ja) * | 1985-06-03 | 1987-01-13 | イ−ストマン コダック カンパニ− | 全乳酸デヒドロゲナ−ゼ量の測定用分析要素及びその測定方法 |
JPH04501768A (ja) * | 1988-09-15 | 1992-03-26 | アイ―スタット コーポレーション | 実時間流体分析用使い捨て可能な検知装置 |
JPH09504608A (ja) * | 1993-10-04 | 1997-05-06 | アイ−スタット コーポレーション | 体液試料中の溶血を検出するための方法および装置 |
WO2006121510A2 (en) * | 2005-05-09 | 2006-11-16 | Theranos, Inc. | Point-of-care fluidic systems and uses thereof |
Non-Patent Citations (2)
Title |
---|
JPN6012069058; 産科と婦人科, 71[12](2004) p.1845-1850 * |
JPN6012069059; J. Obstet. Gynaecol. Res., 26[1](2000) p.61-63 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013506833A (ja) * | 2009-09-30 | 2013-02-28 | カルマーク スウェーデン アクチエボラグ | 低酸素誘導性の細胞損傷を測定する検査システム |
JP2021508048A (ja) * | 2017-12-20 | 2021-02-25 | ラジオメーター・メディカル・アー・ペー・エス | インビトロ溶血検出及び全血サンプル中の少なくとも1つの血液パラメータの補正 |
JP2021192046A (ja) * | 2017-12-20 | 2021-12-16 | ラジオメーター・メディカル・アー・ペー・エス | インビトロ溶血検出及び全血サンプル中の少なくとも1つの血液パラメータの補正 |
JP7253595B2 (ja) | 2017-12-20 | 2023-04-06 | ラジオメーター・メディカル・アー・ペー・エス | インビトロ溶血検出及び全血サンプル中の少なくとも1つの血液パラメータの補正 |
Also Published As
Publication number | Publication date |
---|---|
EP2089535A4 (en) | 2015-03-18 |
US20150127078A1 (en) | 2015-05-07 |
EP2089535A2 (en) | 2009-08-19 |
WO2008054303A3 (en) | 2008-06-05 |
US20080213744A1 (en) | 2008-09-04 |
SE530596C2 (sv) | 2008-07-15 |
WO2008054303A2 (en) | 2008-05-08 |
JP5655307B2 (ja) | 2015-01-21 |
CN101535497A (zh) | 2009-09-16 |
US8945824B2 (en) | 2015-02-03 |
SE0602158L (sv) | 2008-04-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5655307B2 (ja) | 分娩時の頭皮血液における低酸素症を確認する方法 | |
Soothill et al. | Effect of gestational age on fetal and intervillous blood gas and acid-base values in human pregnancy | |
Sagen et al. | Serum urate as a predictor of fetal outcome in severe pre‐eclampsia | |
SE534542C2 (sv) | Testsystem för bestämning av hypoxiutlöst cellskada | |
Wiberg‐Itzel et al. | Lactate determination in vaginal fluids: a new method in the diagnosis of prelabour rupture of membranes | |
CN101025415A (zh) | 一种检测尿液中尿酸含量范围的试纸 | |
WO2013008239A1 (en) | Noninvasive detection of meconium in amniotic fluid | |
Dudenhausen et al. | Umbilical artery blood gases in healthy term newborn infants | |
KR19990071473A (ko) | 자궁내 태변 검출 시스템 | |
EP2396419A1 (en) | Method of determining hypoxia | |
Horger III et al. | Diagnostic use of amniotic fluid | |
CN207741981U (zh) | 一种方便女性糖尿病患者尿糖检测用尿液收集装置 | |
Zygula et al. | Saliva, hair, tears, and other biological materials obtained non-invasively for diagnosis in pregnancy: a literature review | |
Chatterjee et al. | Fetal tissue pH‐continuous intrapartum monitoring | |
ES2687971T3 (es) | Diagnóstico de sufrimiento fetal | |
CN211122639U (zh) | 一种带心率血氧检测的多参数电化学检测仪 | |
Iorizzo | Secondary Tools to Cardiotocography for Fetal Monitoring during Labor | |
JP4272937B2 (ja) | 糞便採取用具 | |
North | Classification and diagnosis of pre-eclampsia | |
CN114019173B (zh) | 用于预测非综合征型唇腭裂的标志物及其应用 | |
Stempel et al. | Diagnosis of fetal death in utero with amniotic fluid creatine kinase | |
Ecker et al. | Obstetric evaluation of fetal acid-base balance | |
Rinala et al. | Correlation of glucose concentrations in maternal serum and amniotic fluid in high-risk pregnancies | |
RU2407433C1 (ru) | Способ диагностики гестоза у беременных | |
Ferber et al. | Nucleated red blood cells in human fetal scalp capillary blood samples: a feasibility study |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100720 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110622 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130115 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130410 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130510 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130515 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130531 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130614 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130710 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130712 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140408 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140704 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140731 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140808 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20141014 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20141110 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5655307 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |